BMS, Gilead report data from combo HCV trial

Bristol-Myers Squibb Co. (NYSE:BMY) and Gilead Sciences Inc. (NASDAQ:GILD) reported interim data from the Phase IIa AI-444040 trial evaluating three treatment regimens of BMS's daclatasvir and Gilead's GS-7977. In the trial, 100% of patients with HCV genotype 1 infection and 88% of patients with HCV genotype 2/3 infection achieved a sustained virologic response (SVR) four weeks after completing treatment with once-daily GS-7977 for seven days followed by 23 weeks of daclatasvir plus GS-7977. Additionally, 100% of patients with either genotype 1 or genotype 2/3 infection achieved an SVR4 after completing treatment with daclatasvir plus GS-7977 for 24 weeks. Furthermore, 100% of patients with genotype 1 and 86% of patients with genotype 2/3 infection achieved an SVR4 after completing treatment with daclatasvir plus GS-7977 and ribavirin for 24 weeks. The open-label trial enrolled 88 non-cirrhotic treatment-naive patients with chronic HCV genotype 1, 2 or 3 infection. Data were presented at the European Association for the Study of the Liver meeting in Barcelona.

Based on the data, Bristol-Myers said it was interested in a Phase III collaboration with Gilead to evaluate daclatasvir in combination with GS-7977. However, Bristol-Myers said that "Gilead was not interested." Gilead said it is in the process of considering all the available data. ...